Premature ejaculation and pharmaceutical company-based medicine: The dapoxetine case

Journal of Sexual Medicine

Volumn 5, Issue 4, 2008, Pages 966-997

  Waldinger, Marcel D ^a,b   Schweitzer, Dave H ^c  

^a LEYENBURG HOSPITAL   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c REINIER DE GRAAF HOSPITAL   (Netherlands)

Author keywords

Adverse Effects; Dapoxetine; Geometric Mean IELT; Premature Ejaculation; SSRIs

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ANTIDEPRESSANT AGENT; CAPTOPRIL; CLOMIPRAMINE; CODEINE; DAPOXETINE; DULOXETINE; FLECAINIDE; LORATADINE; METOPROLOL; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; NEUROLEPTIC AGENT; PAROXETINE; PLACEBO; PROPAFENONE; PROPRANOLOL; QUINIDINE; RITONAVIR; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; TROPISETRON; VENLAFAXINE; VINBLASTINE;

ARTICLE; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; EMBASE; ERECTILE DYSFUNCTION; FOOD AND DRUG ADMINISTRATION; HUMAN; LIBIDO DISORDER; MALE; MEDLINE; OFF LABEL DRUG USE; PATIENT SATISFACTION; PREMATURE EJACULATION; PRIORITY JOURNAL; QUESTIONNAIRE;

EID: 38649101927     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2008.00633.x     Document Type: Article

References (67)

1. Gross S. Practical Treatise on Impotence and Sterility. Edinburgh: YJ Pentland; 1887.
2. Waldinger MD. Lifelong premature ejaculation: From authority based to evidence based medicine. Br J Urol Int 2004; 93: 201-7.
3. Waldinger MD. Evolution of the understanding of premature ejaculation: Historical perspectives. Eur Urol 2007;6 (13 suppl): 761-86.
4. Hamilton CL, Cornpropst JD. Determination of dapoxetine, an investigational agent with the potential for treating depression, and its mono- and di-desmethyl metabolites in human plasma using column-switching high-performance liquid chromatography. J Chromatogr 1993; 612: 253-61.
5. [No authors listed]. Dapoxetine: LY210448. Drugs in R&D 2005; 6: 307-11.
6. Dresser MJ, Kang D, Staehr P, Gidwani S, Guo C, Mulhall JP, Modi NB. Pharmacokinetics of dapoxetine, a new treatment for premature ejaculation: Impact of age and effects of a high-fat meal. J Clin Pharmacol 2006; 46: 1023-9.
7. Dresser MJ, Desai D, Gidwani S, Seftel AD, Modi NB. Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors. Int J Impot Res 2006; 18: 104-10.
8. Andersson KE, Mulhall JP, Wyllie MG. Pharmacokinetic and pharmacodynamic features of dapoxetine, a novel drug for "on-demand"treatment of premature ejaculation. BJU Int 2006; 97: 311-5.
9. Modi NB, Dresser MJ, Simon M, Lin D, Desai D, Gupta S. Single- and multiple-dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation. J Clin Pharmacol 2006; 46: 301-9.
10. Modi NB, Dresser M, Desai D, Edgar C, Wesnes K. Dapoxetine has no pharmacokinetic or cognitive interactions with ethanol in healthy male volunteers. J Clin Pharmacol 2007; 47: 315-22.
11. Pryor JL, Althof SE, Steidle C, Rosen RC, Hellstrom WJ, Shabsigh R, Miloslavsky M, Kell S. Dapoxetine Study Group. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: An integrated analysis of two double-blind, randomised controlled trials. Lancet 2006; 368: 929-37.
12. Sharlip I. Diagnosis and treatment of premature ejaculation: The physician's perspective. J Sex Med 2005; 2 (2 suppl): 103-9.
13. Hellstrom WJG, Nehra A, Shabsigh R, Sharlip ID. Premature ejaculation: The most common male sexual dysfunction. J Sex Med 2006; 3 (1 suppl): 1-3.
14. Hellstrom WJ. Current and future pharmacotherapies of premature ejaculation. J Sex Med 2006; 3 (4 suppl): 332-41.
15. Hellstrom WJ, Heintz JW. Treatment of premature ejaculation: New drugs and treatment strategies. Curr Urol Rep 2006; 7: 473-8.
16. Mulhall JP. Current and future pharmacotherapeutic strategies in treatment of premature ejaculation. Urology 2006; 67: 9-16.
17. Moreland AJ, Makela EH. Selective serotonin-reuptake inhibitors in the treatment of premature ejaculation. Ann Pharmacother 2005; 39: 1296-301.
18. McMahon CH. The etiology and management of premature ejaculation. Nat Clin Pract Urol 2005; 2: 426-33.
19. Wylie KR, Ralph D. Premature ejaculation: The current literature. Curr Opin Urol 2005; 15: 393-8.
20. Waldinger MD. Lifelong premature ejaculation: Definition, serotonergic neurotransmission and drug treatment. World J Urol 2005; 23: 102-8.
21. Waldinger MD. Lifelong premature ejaculation: Current debate on definition and treatment. J Men's Health Gend 2005; 2: 333-8.
22. Waldinger MD. Drug treatment of premature ejaculation: Pharmacodynamic and pharmacokinetic paradigms. Drug Discovery Today: Ther Strat 2005; 2: 37-40.
23. Waldinger MD. Overview of premature and retarded ejaculation. Eur Urol Today 2005; 17: 20-2.
24. Riley A, Segraves RT. Treatment of premature ejaculation. Int J Clin Pract 2006; 60: 694-7.
25. Segraves RT. Rapid ejaculation: A review of nosology, prevalence and treatment. Int J Impot Res 2006; 18: S24-32.
26. Schuster TG. Premature ejaculation. Urol Nurs 2006; 26: 245-9.
27. Safarinejad MR, Hosseini SY. Pharmacotherapy for premature ejaculation. Curr Drug Ther 2006; 1: 37-46.
28. Richardson D, Goldmeier D, Green J, Lamba H, Harris JRW. Recommendations for the management of premature ejaculation: BASHH special interest group for sexual dysfunction. Int J STD AIDS 2006; 17: 1-6.
29. Waldinger MD. Emerging drugs for premature ejaculation. Expert Opin Emerg Drugs 2006; 11: 99-109.
30. Waldinger MD. Premature ejaculation: Definition and drug treatment. Drugs 2007; 67: 547-68.
31. Waldinger MD. Premature ejaculation. Prim Psychiatr 2007; 14: 58-64.
32. de Jong TR, Pattij T, Veening JG, Dederen PJ, Waldinger MD, Cools AR, Olivier B. Citalopram combined with WAY 100635 inhibits ejaculation and ejaculation-related Fos immunoreactivity. Eur J Pharmacol 2005; 509: 49-59.
33. de Jong TR, Pattij T, Veening JG, Waldinger MD, Cools AR, Olivier B. Effects of chronic selective serotonin reuptake inhibitors on 8-OH-DPAT-induced facilitation of ejaculation in rats: Comparison of fluvoxamine and paroxetine. Psychopharmacology (Berl) 2005; 179: 509-15.
34. Pattij T, Olivier B, Waldinger MD. Animal models of ejaculatory behaviour. Curr Pharm Des 2005; 11: 4069-77.
35. Waldinger MD, Olivier B. Animal models of premature and retarded ejaculation. World J Urol 2005; 23: 115-8.
36. Pattij T, de Jong T, Uitterdijk A, Waldinger MD, Veening JG, van der Graaf PH, Olivier B. Individual differences in male rat ejaculatory behavior: Searching for models to study ejaculation disorders. Eur J Neurosci 2005; 22: 724-34.
37. de Jong TR, Pattij T, Veening JG, Dederen J, Waldinger MD, Cools AR, Olivier B. Effects of chronic paroxetine pretreatment on (+/-)-8-hydroxy-2-(di-n-propyl-amino) tetralin induced c-fos expression following sexual behavior. Neuroscience 2005; 134: 1351-61.
38. Olivier B, Chan JS, Pattij T, de Jong TR, Oosting RS, Veening JG, Waldinger MD. Psychopharmacology of male rat sexual behavior: Modeling human sexual dysfunctions? Int J Impot Res 2006; 18 (1 suppl): S14 -23.
39. Giuliano F, Clement P. Serotonin and premature ejaculation: From physiology to patient management. Eur Urol 2006; 50: 454-66.
40. de Jong TR, Veening JG, Waldinger MD, Cools AR, Olivier B. Serotonin and the neurobiology of the ejaculatory threshold. Neurosci Biobehav Rev 2006; 30: 893-907.
41. de Jong TR, Snaphaan LJ, Pattij T, Veening JG, Waldinger MD, Cools AR, Olivier B. Effects of chronic treatment with fluvoxamine and paroxetine during adolescence on serotonin-related behavior in adult male rats. Eur Neuropsychopharmacol 2006; 16: 39-48.
42. Giuliano F. 5-hydroxytryptamine in premature ejaculation: Opportunities for therapeutic intervention. Trends Neurosci 2007; 30: 79-84.
43. Clement P, Bernabe J, Gengo P, Denys P, Laurin M, Alexandre L, Giuliano F. Supraspinal site of action for the inhibition of ejaculatory reflex by dapoxetine. Eur Urol 2007; 51: 825-32.
44. Giuliano F, Bernabe J, Gengo P, Alexandre L, Clement P. Effect of acute dapoxetine administration on the pudendal motoneuron reflex in anesthetized rats: Comparison with paroxetine. J Urol 2007; 177: 386-9.
45. de Jong TR, Veening JG, Olivier B, Waldinger MD. Oxytocin involvement in SSRI-induced delayed ejaculation: A review of animal studies. J Sex Med 2007; 4: 14-28.
46. Safarinejad MR. Comparison of dapoxetine versus paroxetine in patients with premature ejaculation: A double-blind, placebo-controlled, fixed-dose, randomized study. Clin Neuropharmacol 2006; 29: 243-52.
47. Waldinger MD, Schweitzer DH, Olivier B. Dapoxetine treatment of premature ejaculation (letter). Lancet 2006; 368: 1869-70.
48. Waldinger MD. The authors reply (letter). Drugs 2007; 67: 1630-2.
49. Waldinger MD, Zwinderman AH, Olivier B. On-demand treatment of premature ejaculation with clomipramine and paroxetine: A randomized, double-blind fixed-dose study with stopwatch assessment. Eur Urol 2004; 46: 510-6.
50. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side-effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987; 76 (334 suppl): 1 -100.
51. Touw DJ. Clinical implications of genetic polymorphisms and drug interactions mediated by cytochrome P-450 enzymes. Drug Metabol Drug Interact 1997; 14: 55-82.
52. Informatorium Medicamentorum. Chapter: Psychofarmaca, Serotonine Heropname Remmers. Den Haag: KNMP; 2007: 868-84.
53. Philipp M, Tiller JW, Baier D, Kohnen R. Comparison of moclobemide with selective serotonin reuptake inhibitors (SSRIs) on sexual function in depressed adults. The Australian and German Study Groups. Eur Neuropsychopharmacol 2000; 10: 305-14.
54. Waldinger MD, Zwinderman AH, Olivier B, Schweitzer DH. Majority of men with lifelong premature ejaculation prefer daily drug treatment: An observational study in a consecutive group of Dutch men. J Sex Med 2007; 4: 1028-37.
55. Waldinger MD, Hengeveld MW, Zwinderman AH, Olivier B. A double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine and sertraline. J Clin Psychopharmacol 1998; 18: 274-81.
56. Waldinger MD, Zwinderman AH, Schweitzer DH, Olivier B. Relevance of methodological design for the interpretation of efficacy of drug treatment of ejaculation: A systematic review and meta-analysis. Int J Impot Res 2004; 16: 369-81.
57. Waldinger MD, Schweitzer DH, Olivier B. On-demand SSRI treatment of premature ejaculation: Pharmacodynamic limitations for relevant ejaculation delay and consequent solutions. J Sex Med 2005; 2: 120-31.
58. Waldinger MD, Hengeveld MW, Zwinderman AH, Olivier B. An empirical operationalization study of DSM-IV diagnostic criteria for premature ejaculation. Int J Psychiatr Clin Pract 1998; 2: 287-93.
59. Waldinger MD, Schweitzer DH. Changing paradigms from an historical DSM-III and DSM-IV view towards an evidence based definition of premature ejaculation. Part I: Validity of DSM-IV-TR. J Sex Med 2006; 3: 682-92.
60. Waldinger MD, Schweitzer DH. Changing paradigms from an historical DSM-III and DSM-IV view towards an evidence based definition of premature ejaculation. Part II: Proposals for DSM-V and ICD-11. J Sex Med 2006; 3: 693-705.
61. Waldinger MD. The need for a revival of psychoanalytic investigations into premature ejaculation. J Men's Health Gend 2006; 3: 390-6.
62. Waldinger MD, Schweitzer DH. The DSM-IV-TR is an inadequate diagnostic tool for premature ejaculation (letter). J Sex Med 2007; 4: 822-3.
63. Pryor JL. Author's reply. Lancet 2006; 368: 1869-70.
64. Balon R. Depression, antidepressants, and human sexuality. Prim Psychiatr 2007; 14: 42-50.
65. Hellstrom WJG. The DSM-IV-TR is an appropriate diagnostic tool for premature ejaculation. J Sex Med 2007; 4: 252.
66. Patrick DL, Rowland D, Rothman M. Interrelationships among measures of premature ejaculation: The central role of perceived control. J Sex Med 2007; 4: 780-8.
67. Shabsigh R, Rowland D. The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision as an appropriate diagnostic for premature ejaculation. J Sex Med 2007; 4: 1468-78.